معرفی
Galina Selivanova is a **Professor of Cell and Tumor Biology** at **Karolinska Institutet**, Stockholm. She leads the Galina Selivanova Group within the Division of Tumor Biology, focusing on developing small molecules to restore p53 tumor suppression functions. Her work bridges molecular biology, cancer research, and drug development.
Education and Career:
- **Docent** degree from Karolinska Institutet (2002)
- Professor (2010–2025), Senior Professor (2025–present) in the Department of Microbiology, Tumor and Cell Biology.
Research Focus:
Her pioneering research centers on the p53 protein, a key tumor suppressor. Projects include:
- Pharmacological reactivation of mutant p53 and its role in cancer immune escape.
- Design of small molecules like APR-246/APR-246 and RITA analogs targeting oncogenic pathways.
- Exploring synergistic therapies combining p53 reactivation with immunotherapy or chemotherapy.
Grants:
- Swedish Research Council (e.g., 2020–2023 grant targeting p53-driven immune responses).
- Swedish Cancer Society (multiple grants since 2015 for p53-based cancer therapy research).
- Wallenberg Foundation (2013–2018) for pro-senescence therapy in melanoma.
Lab and Collaborations:
Her group collaborates internationally to advance translational oncology, emphasizing drug design, molecular mechanisms, and clinical relevance. Key projects involve thermal proteome profiling, network biology, and preclinical drug testing.